New AHSA Rule Change Proposal Is On The Table

A new AHSA drugs and medications rule change proposal has emerged as a result of the June 1 AHSA Drugs and Medications Committee meeting. The new proposal, which would permit the therapeutic use of two NSAIDs, will be presented in final form and voted upon at the January 1999 AHSA annual meeting. (This does not affect the interim revised rules which took effect June 1, 1998 (see posting of this rule change at the end of this news section).

The new proposal would permit combinations of the five permitted d NSAIDs other than phenylbutazone and flunixin together. The maximum permitted plasma concentrations are consistent with the administration of NSAIDs in accordance with the AHSA's dose and time recommendations, i.e., a therapeutic dose not closer than 12 hours prior to competition (exception: in the case of phenylbutazone, half the daily dose administered orally each 12 hours).

Earlier this year, the National Hunter Jumper Council submitted a proposal that would include maximum permitted plasma concentrations of NSAIDs consistent with administrations at six hours prior to competition. A rule that establishes plasma levels of NSAIDs consistent with six hour administrations would be difficult if not impossible to enforce. The resulting plasma concentrations at six hours would be so large that it would not be possible to determine that a therapeutic dose was administered within this period of time. The large numbers arise due to variations in absorption and distribution of the drugs, which are the dominant pharmaconkinetic parameters hortly after drug administration. The greatest variations in concentration are observed with oral administrations and the least with intravenous administrations..

The following proposal, drafted June 1, 1998, includes provisions for minimum fines for the first, second and third violations. It also includes a provision for adding new NSAIDs to the list of those permitted to be used.

AHSA NSAID Rule Change Proposal

To be effective on March 1, 1999

Article 410. Drugs and Medications. The Therapeutic Substance Provisions.

Amend Article 410.4 as follows:

4. Restrictions concerning the nonsteriodal anti-inflammatory drugs are as follows:

(a). The maximum permitted plasma concentration of phenylbutazone is 15.0 micrograms per milliliter.

(b) The maximum permitted plasma concentration of flunixin is 1.0 micrograms per milliliter.

(c) The maximum permitted plasma concentration of ketoprofen is 0.040 micrograms per milliliter.

(d) The maximum permitted plasma concentration of meclofenamic acid is 1.0 micrograms per milliliter.

(e) The maximum permitted plasma concentration of naproxen is 20.0 micrograms per milliliter.

(f) Not more than two of the substances listed in (a) through (e) above are permitted to be present in the same plasma or urine sample (Article 411 does not apply).

(g) Phenylbutaxone and flunixin are not permitted to be present in the same plasma or urine sample (Article 411 does not apply).

(h) Any nonsteroidal anti-inflammatory drug not listed in (a) through (e) above is forbidden to be present in the plasma or urine sample (Article does not apply); exception salicylic acid.

(i) In any instance two nonsteriodal anti-inflammatory drugs are administered, a medication report must be completed and filed in accordance with Article 411.

(j) Any nonsteroidal anti-inflammatory drug that becomes approved for use in horses can be added to the list of those permitted, in accordance with the procedures for a standard rule change, after the completion, review and approval of the needed research.

Add new Section 5 as follows:

5. Minimum penalties for violating Article 410.4 above are as follows.

a. First offense: $1,000.
b. Second offense: $1,500.
c. Third offense: $2,500.

Renumber old articles 410.5 through 7 to be 410.6 to 8.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners